FDA Office of New Drugs vs Office of Drug Safety: Structural Conflict and the 2007 Amendments Act

In the early 2000s, the FDA's drug-evaluation function was institutionally divided between two offices with conflicting incentives. The Office of New Drugs approved drug applications, was substantially funded through industry user fees under the Prescription Drug User Fee Act, and had career-advancement incentives tied to throughput of approvals. The Office of Drug Safety monitored drugs after approval, was politically weaker, and was chronically underfunded. When Office of Drug Safety analyst David Graham compiled his Kaiser Permanente study of over one million real-world Vioxx patients showing a 3.7-times heart attack risk at high doses, his supervisor described the analysis as 'junk science.' Internal FDA management pressured Graham to soften his conclusions before his 2004 Senate Finance Committee testimony. The structural problem was that if the Office of Drug Safety declared Vioxx a killer, the Office of New Drugs had implicitly made a serious mistake by approving it. The agency had institutional reasons to defer to its own prior approval rather than allow its safety arm to contradict it. This is a textbook case of regulatory capture arising from organizational structure rather than from corruption — no individual villainy required, only misaligned incentives. The FDA Amendments Act of 2007 (FDAAA) was the direct legislative response to the Vioxx withdrawal. It gave the FDA expanded authority to mandate post-market safety studies, require public registration and results disclosure for clinical trials, and enforce label changes when post-market evidence warranted. The Office of Drug Safety was strengthened with formal authority that did not depend on cooperation from the Office of New Drugs. The underlying profit-versus-safety tension remained structural, but the post-Vioxx reforms gave the safety side institutional teeth it had previously lacked.